Immunic, Inc., through the acquisition of the assets and operations of VitaGen Corporation, commenced operations as a California corporation on May 23, 2003 and changed its name to Vital Therapies, Inc., in June 2003. In January 2004, the company was incorporated again in Delaware. Immunic is a late-stage biotechnology company focused on the development of novel oral therapies for the treatment of neurological and gastrointestinal diseases. The company is headquartered in New York City, with principal operations in Graffelfen, near Munich, Germany. Immunic is committed to advancing the clinical development of small molecule drug programs designed to meet the unmet medical needs of patients with severe chronic inflammation and autoimmune diseases. This includes the vidofludimus calcium program (for the treatment of relapsing multiple sclerosis patients), which is currently in phase III clinical development, as well as other programs for various gastrointestinal and autoimmune diseases.
